Q-omics provides the consensus-scored RPLP0P6 profile across patient tissues and cancer cell-line models. RPLP0P6 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPLP0P6 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RPLP0P6 RNA expression shows 16,211 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where RPLP0P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPLP0P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPLP0P6 survival associations across molecular data types. RPLP0P6 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPLP0P6 RNA expression–survival associations across cancer types. High RPLP0P6 expression shows unfavorable associations in ACC, KICH, KIRP, LIHC and LUAD, but favorable associations in UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPLP0P6 RNA expression.
This table summarizes RPLP0P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RPLP0P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPLP0P6 shows higher tumor expression in KIRC, COAD, LIHC, KIRP, CHOL and LUSC. The KIRC box plot shows higher RPLP0P6 RNA expression in tumor versus normal tissue (log2 FC = +1.127, t-test p < 0.001).
This table shows molecular features associated with RPLP0P6 in patient tissues and cancer cell lines. In patient samples, RPLP0P6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
